ABCC1 and colorectal cancer: In addition, it will be interesting to observe the outcomes of the phase III clinical trial that is currently recruiting colorectal cancer-suffering patients (NCT04607421) and is going to evaluate the combination of encorafenib with ABCC1 substrates (irinotecan, 5-fluorouracil).